TimesSquare Capital Management LLC Has $25.46 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

TimesSquare Capital Management LLC grew its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 8.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,827,695 shares of the company's stock after buying an additional 139,160 shares during the period. TimesSquare Capital Management LLC owned 1.81% of Day One Biopharmaceuticals worth $25,460,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in shares of Day One Biopharmaceuticals by 19.8% in the first quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company's stock valued at $33,575,000 after acquiring an additional 336,281 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Day One Biopharmaceuticals by 517.0% during the 2nd quarter. AQR Capital Management LLC now owns 113,020 shares of the company's stock valued at $1,557,000 after purchasing an additional 94,703 shares during the period. ProShare Advisors LLC raised its stake in shares of Day One Biopharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company's stock worth $287,000 after buying an additional 1,447 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Day One Biopharmaceuticals by 65.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company's stock valued at $40,281,000 after buying an additional 1,157,825 shares in the last quarter. Finally, Essex Investment Management Co. LLC acquired a new position in Day One Biopharmaceuticals during the third quarter worth about $2,566,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Trading Down 3.2 %

NASDAQ DAWN traded down $0.53 on Monday, reaching $15.86. The stock had a trading volume of 934,093 shares, compared to its average volume of 954,734. Day One Biopharmaceuticals, Inc. has a 1 year low of $10.90 and a 1 year high of $18.07. The business has a 50 day moving average price of $14.38 and a 200 day moving average price of $14.40. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -15.40 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same period in the previous year, the company earned ($0.54) earnings per share. On average, analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Bank of America upgraded shares of Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and boosted their target price for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. JPMorgan Chase & Co. decreased their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating for the company in a report on Tuesday, August 6th. Wedbush restated an "outperform" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Needham & Company LLC restated a "buy" rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of "Buy" and an average price target of $35.71.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 2,232 shares of the firm's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the sale, the insider now owns 1,127,535 shares in the company, valued at approximately $15,785,490. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Samuel C. Blackman sold 11,245 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $16.03, for a total transaction of $180,257.35. Following the sale, the insider now directly owns 1,085,790 shares of the company's stock, valued at $17,405,213.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Samuel C. Blackman sold 2,232 shares of the company's stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the transaction, the insider now directly owns 1,127,535 shares of the company's stock, valued at approximately $15,785,490. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,493 shares of company stock worth $877,339. Company insiders own 8.40% of the company's stock.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.